Skip to main content
ROVI Subsidiaries
Spain
Germany
France
Italy
Poland
Portugal
United Kingdom
Language
Spanish
Spanish
English
English
English
Español
Home
ROVI
History
Group structure
Business units
International expansion
Strategy
Licenses
Contact
Products
Prescription Pharmaceuticals
Hospital Products
Manufacturing
CDMO
Own product Manufacturing
R&D
Shareholders and Investors
The share
Investor's Calendar
News
Financial and Business Information
CMNV Communications
ESG
Corporate Governance
Telematic assistance access
Prior Registration On-Line Attendance
On-Line Attendance
Sustainability
Responsible governance
Commitment to people
Environmental Commitment
Ethics Channel
Media
FAQS
News
ROVI up to date
Contact
Work with Us
TELEMATIC ASSISTANCE ACCESS
Home
News
2018 full year results presentation
Operating income, growth figures, profitability and how our products have behaved.
Tue, 26/02/2019 - 11:15
0 min
Español
IMG_0281.jpg
Download related document
Select rating
Give 2018 full year results presentation 1/5
Give 2018 full year results presentation 2/5
Give 2018 full year results presentation 3/5
Give 2018 full year results presentation 4/5
Give 2018 full year results presentation 5/5
No votes yet
Related
Full Year 2019 results presentation
0 min
26/02/2020
ROVI reports operating revenue growth of 26% and EBITDA growth of 106%
Operating revenue increased by 26% to 381.3 million euros in 2019, mainly driven by the strength of the specialty pharmaceutical...
6 min
26/02/2020
ROVI announces the commencement of the assessment process to obtain marketing...
ROVI filed its application for marketing authorisation for Doria® with the European health authorities, the European Medicines Agency (EMA...
2 min
31/01/2020
See More
Email
Facebook
Twitter
LinkedIn
IMG_0281.jpg